Patents Examined by Julie Wu
  • Immunotherapy with binding agents
    Patent number: 9833500
    Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 5, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Fumiko Takada Axelrod
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 9822186
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 21, 2017
    Assignee: XENCOR, INC.
    Inventors: Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
  • Monospecific polypeptide reagents
    Patent number: 9815891
    Abstract: The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 14, 2017
    Inventor: Robert Poppe
  • LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same
    Patent number: 9783599
    Abstract: The invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to LM-1 antigen (e.g., NONO/nmt55). Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a LM-1 antibody, an antibody that binds to LM-1 antigen, or a functional fragment thereof, effective to treat metastasis of the neoplasia, tumor or cancer in the subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 10, 2017
    Assignee: Patrys Limited
    Inventors: Heinz Peter Vollmers, Stephanie Ute Brandlein, Andreas Thalheimer, Leodevico L. Ilag, Barbara E. Power, Lishanthi Udabage, Frank Hensel, Frank Schoenen, Arndt-Rene Kelter, Christopher Garth Hosking
  • Anti-HER3 antibodies binding to the beta-hairpin of HER3
    Patent number: 9783611
    Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 10, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Anti-DPEP3 antibodies and methods of use
    Patent number: 9777071
    Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
  • TEM-1 diagnostic antibodies
    Patent number: 9771429
    Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: September 26, 2017
    Assignee: Morphotek, Inc.
    Inventor: Daniel John O'Shannessy
  • MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
    Patent number: 9770499
    Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 26, 2017
    Assignee: Ruprecht-Karls-Universitat Heidelberg
    Inventors: Matthias Kloor, Miriam Reuschenbach, Magnus von Knebel-Doeberitz
  • Immunological compositions as cancer therapeutics
    Patent number: 9745377
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 29, 2017
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • Antibodies directed against signal peptides, methods and uses thereof
    Patent number: 9732153
    Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 15, 2017
    Assignee: VAXIL BIOTHERAPEUTICS LTD.
    Inventors: Lior Carmon, Riva Kovjazin
  • Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
    Patent number: 9717781
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: August 1, 2017
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Enzymatic conjugation of polypeptides
    Patent number: 9717803
    Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 1, 2017
    Assignees: INNATE PHARMA, PAUL SCHERRER INSTITUT
    Inventors: Delphine Bregeon, Patrick Dennler, Christian Belmant, Eliane Fischer, Laurent Gauthier, Francois Romagné, Roger Schibli
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 9714296
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: July 25, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Monoclonal antibodies against HER2 epitope
    Patent number: 9714294
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 25, 2017
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 9714295
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: July 25, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Method for preparing homodimer protein mixture by using charge repulsion effect
    Patent number: 9708389
    Abstract: The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: July 18, 2017
    Assignee: Suzhou Alphamab Co., Ltd.
    Inventors: Ting Xu, Tao Xu, Xiaoxiao Wang, Xinglu Sun, Ying Fan, Yan Zeng
  • Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
    Patent number: 9701740
    Abstract: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: July 11, 2017
    Assignees: YALE UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Peter M. Glazer, Richard H. Weisbart, Robert N. Nishimura, Grace Chan
  • Anti-CD98 antibody processes
    Patent number: 9688770
    Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: June 27, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
  • Single-chain antibodies and other heteromultimers
    Patent number: 9688758
    Abstract: The invention provides engineered heteromultimeric protein complexes constructed using one, two, or three tethers and methods for making, using, and purifying such complexes, such as antibodies with different binding properties.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: June 27, 2017
    Assignee: GENENTECH, INC.
    Inventors: Bernd Wranik, Dan L. Eaton, Erin H. Christensen, Jiansheng Wu
  • Immunoglobulins with reduced aggregation
    Patent number: 9676841
    Abstract: The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 13, 2017
    Assignees: Novartis AG, Massachusetts Institute of Technology
    Inventors: Naresh Chennamsetty, Bernhard Helk, Veysel Kayser, Bernhardt Trout, Vladimir Voynov